Voters in Oxford, “the home of liberal intellectualism”, demonstrated their overwhelmingsupport for electoral reform by voting Yes in last week’s AV referendum, in contrast to the majority of the rest of the country.After two recounts, it was declared that those in the Yes camp had beaten those favouring the “First Past The Post” (FPTP) system by 21,693 votes to 18,395.The majority of voters in Cambridge also voted in support of AV. Nearly four thousand more votes were cast for Yes than for No.North London constituencies including Islington, Haringey and Camden equally followed this trend.However, only 10 out of 440 national constituencies had a majority vote favouring AV.Andrew Mell, Oxfordshire Press Officer for the YES campaign and an Economics student at Nuffield, said more people in Oxford voted in favour of AV because of an effective campaign which “engaged with all parts of the community”.Oxford City’s result did not match the national consensus. 6.1 million people voted in favour of electoral reform across the country, as opposed to the 13 million who rejected it.Mell said that it was time for those behind the Yes campaign to hold a “post-mortem” to “work out what went wrong”.Sam Robberts, an OUCA member from Christ Church, said that both campaigns had centred on “demonisation” of the opposition.Robberts told Cherwell that he voted NO in order to preserve Britain’s voting culture.“I was concerned that the increased consensual politics the Yes campaign required would in fact lead to greater voter apathy”, he said.Robberts admitted that Oxford’s liberal stance hardly came as a shock.“I am not surprised that Oxford and Cambridge, and North London voted yes”, he said.“They are traditionally seen as the home of liberal intellectualism in this country, and it is good to see that those people at least stuck to their principles and delivered the result they wanted.”
Dried fruit industry innovator Andy Humphries has launched a new company, Electric Cherry.Humphries is promising to “shake up” the sector with a focus on added-value products.The initial range includes whole, halved, quartered and diced figs, dates and apricots (natural and preserved) and has already attracted the attention of retail packers and ingredient suppliers.Humphries, who has held leading positions at dried fruit suppliers Humdinger, Mariani and Community Foods, said: “There is no shortage of people importing dried fruit, but nobody is doing what we’re doing.”As to exactly what this is, he said: “Providing the highest quality dried fruit from trusted growers in different formats. This opens up potential among our customers for new product development, more interesting and exciting retail mixes and all-round innovation.”He added; “In a sector where the fruit on offer has been pretty much the same forever, Electric Cherry is delivering something different. Although we have only been trading for a few weeks, we are already getting repeat orders, with lines such as apricot halves and fig quarters proving particularly popular.”Humphries said Electric Cherry only works with leading dried fruit suppliers and has a number of strategic alliances already in place. It has also embarked on its own NPD programme, with a focus on fruit with added natural flavours.“The early results are very exciting,” said Humphries, “and it is clear that there is huge scope for more innovation within this sector. If it ever was, dried fruit is no longer dull.”
As much of the developed world continues to dig out from the impact of the 2008 financial crisis, a team of researchers at Harvard and in London has created a model of bank failure aimed at helping economies avoid crashes. Their work highlights a fundamental dilemma for regulators: Improving the safety of individual banks may make the financial system as a whole more dangerous.Developed by Nicholas Beale, chairman of Sciteb, a consulting firm based in London, and David Rand and Martin Nowak, researchers at Harvard’s Program for Evolutionary Dynamics, the model considers risks to financial systems rather than those faced only by individual banks. The team’s paper, Individual Versus Systemic Risk and the Regulator’s Dilemma, appears online in the Proceedings of the National Academy of Science Early Edition.“We used a simple model to illustrate an idea that, on reflection, people understand instinctively,” says Rand. “When many banks do the same thing, simultaneous bank failures become very likely.”Therefore, the authors argue, it is not enough to ensure that every bank is diversified and pursuing a low-risk strategy. “You want the banks to be diversified,” Rand says, “but in different ways, so that the conditions that would cause one bank to fail would be different than the conditions that would cause another bank to fail.” Regulators should therefore promote “diverse diversification,” and encourage individual banks to pursue risk strategies that are distinct from those of their competitors, even if this increases the risk that any one bank might fail.The good news, according to Rand and Beale, is that the financial crisis has spurred regulators to think about the stability of financial systems as a whole. In this climate, the authors hope regulators will encourage banks to pursue more distinctive strategies in order to create a more resilient financial system. “We believe this can be achieved without a central authority directing the banks in particular areas,” says Beale.Instead, he envisions a regulatory scheme that encourages diversity by basing the amount of capital a bank is required to hold on the extent to which its investment strategy contributes to systemic risk. “With the right regulations, market forces will encourage the banks to make a more robust system. But unless these problems are addressed, having a more uniform global regulatory system could actually make the next crash much worse,” says Beale.“Beale, et al., have contributed an important insight that individual bank-risk diversification does not add up to system diversification,” says Professor Andrew Sheng of Tsinghua University, who is chief adviser to the China Banking Regulatory Commission.Beale says that the team’s focus now is building a global alliance for financial and economic resilience.“We’re bringing together leading academics, regulators, banks, and investors,” he says. “Provided a systemic risk capital is set in a sensible way, we have a chance of avoiding the next crisis.”This work was supported in the United Kingdom by the Man Group and Fidelity Investments, and at Harvard by the John Templeton Foundation. Beale, Rand, and Nowak’s team also included Heather Battey, Karen Croxson, and Robert M. May.
“A Christmas Carol,” the transformative tale by Charles Dickens about the ill-tempered anti-hero Ebenezer Scrooge, is for many an integral part of the literary Christmas canon.Yet few of those familiar with the work likely have heard of its entertaining counterpart, a brief work penned decades ago by a popular Harvard professor. But if listeners tune in to Harvard’s student-run radio station WHRB (95.3 FM) tomorrow evening (Dec. 23), they will hear the late Professor David Owen deliver “In Defense of Scrooge,” his humorous and historic ode to the iconic novella.The broadcast, part of the station’s annual holiday programming on Friday from 7 to 10 p.m., will be preceded by a recording of the original “A Christmas Carol,” starring actor Lionel Barrymore as Scrooge.Owen’s work became a festive holiday tradition at Winthrop House because of his wry wit and insightful intellect. Winthrop’s longtime House master, Owen was also the Gurney Professor of History until his death in 1968. Originally composed by Owen for a Signet Society Christmas dinner, his reading became an annual tradition at the House.“Every year … as part of the entertainment, he would get up and deliver his ‘In Defense of Scrooge,’” said David Elliott ’64, who was the station’s program manager when Owen recorded his ode in 1961 at the suggestion of station member and Harvard alumnus Fred Safier ’63. “It’s a history of Christmas customs given in the framework of defending Scrooge, and he did it in a very warm and amusing way … with a distinctive delivery style.”According to Elliott, the recording, which ran occasionally after its initial broadcast, hasn’t been broadcast in some time. Eager to mark the 50th anniversary of the work’s airing, Elliott, who is the chairman of the trustees of the station and host of the annual Christmas show, suggested that the current station manager air it again.“It’s really a great piece, and it’s a tribute, I think, to Professor Owen, who … was clearly an important figure in the history of our house,” said Charlie Hobbs ’13, who recently became the general manager at the station and was happy to rebroadcast the piece. “One of the proudest things that we are able to do, as the student radio station at Harvard, is to broadcast Harvard traditions.”“It’s an exposition in vivid and colorful terms of Christmas customs,” said Elliott of Owen’s work, which explores the wave of renewed interest in traditional Christmas customs sweeping 1840s England that was fueled in part by the adoption of the Christmas tree, an import from Germany courtesy of Queen Victoria’s German husband, and the development of the Christmas card. Dickens’ tale itself was a part of the nation’s burgeoning interest in Christmas traditions of old.Owen argues in his essay that the world’s most famous Christmas curmudgeon was possibly onto something. Given to indigestion, Scrooge was a man of moderation and wasn’t inclined to overindulge in the type of “marathon eating” common at parties and holiday dinners of the Victorian Age. And one could hardly blame the poor man for trying to avoid a fete where the “bouncing” hostess, his nephew’s wife, was the type “determined that all should have a good time whatever the consequences.” Those parties, mused Owen, were the “beginning of the road that would lead to the office party.”One of the three pesky specters in the story, said the professor, deserved its fair share of blame for not painting an accurate picture of pageantry and commercialization of Christmases yet to come. “Did the ghost,” Owen wondered, “hint that each December 1, Harvard Square would suddenly come out bedizened and bejeweled like an ancient cocotte still hopeful of a comeback?”“What he is saying is that Scrooge was right to resist what would develop into excessive and commercialized displays of supposedly Christmas-related celebration,” said Elliott.In reviving the broadcast, Elliott hopes listeners will revel in the clever prose and historic detail, while remembering a well-loved Harvard scholar.“He was such a warm and admired figure at Harvard at that time. We want to remember him while we are enjoying the detail and the spirit of his ‘Defense of Scrooge.’ ”
The NCAA and the Power Five conferences will have to work harder to prevent major changes to college sports now that Democrats control Congress and the White House. The NCAA and the Power Five collectively spent more than $2 million last year to lobby Congress for a bill that would allow athletes to earn money from endorsements.The lobbyists got most of their wish list into a Republican-backed Senate bill last year. But Democrats are pushing for broader reforms, including guaranteed health care for athletes and revenue sharing. They see college sports reform as a racial and economic justice issue.
At Saint Mary’s, the senior theatre majors are always busy. Seniors Stephanie Johnson and Regan Hattersley have already started preparing for their senior comprehensives and the American College Theatre Festival (ACTF) that is open to all theatre majors, minors and those interested in the arts. A comprehensive is an hour-long play Saint Mary’s senior theatre majors put on every year. The students cast and direct their plays, as well as design the set and costumes.Johnson noted the extensive time commitments theatre majors have to undertake, as she said she has to manage her time between performing in shows, working backstage and juggling her school work.“Not only do theatre majors work hard in the classroom, but we work hard outside of the classroom as well,” she said. “Being in three productions at one time while having a full schedule of classes have perfected my time management skills.”Hattersley said in an email that seniors spend fall semester choosing and analyzing a play.“In the spring we use all of this writing and research to produce our play,” she said. “We have to cast people, hold rehearsals, build a set and generally do everything else that goes into a performance. Then at the end of it all, March 3 for me, we sit back and watch all of our work come together for a one-night performance of our show.”Hattersley said helping a senior with her play, whether by acting in it or working backstage for it, is a “great chance to give back and participate” in the Saint Mary’s sisterhood.“Should you ever need help in any situation, we live in a community where help is reciprocated across the board,” she said. “So put some good karma out there and look out for audition notices early next semester.”Even if you are just an audience member, theatre can be an immersive experience, Hattersley said.“The magic of theatre as an art form is that it is an experience like no other,” she said. “As an audience member, you get to enter the lives of the characters and the world of the play in a one-time-only experience. Theatre is an almost limitless art form. It opens doors that allow for discussion of difficult topics. When you sit in the theatre, you, as the audience, get to be a part of something special.”For theatre majors, the senior comprehensive process helps students critically evaluate and collaborate, Johnson said. “Not only must a student exercise her ability to critically evaluate a piece of theatrical work, but [she] also has to effectively collaborate with her peers in creating the piece, as theatre is an art form which can not be effectively accomplished alone — unless one is doing a one-woman show,” Johnson said.If a student has never acted before but has always wanted to, Johnson said the senior comprehensives are a great way to to gain experience. “Working with your friends as they develop their passions is fun,” she said. “It is a learning experience and an opportunity to make new friendships.”Junior Rebecca Strom, who has a theatre minor, said she acted in a senior comprehensive show her freshman year, an adaptation of “Alice in Wonderland.” She also stage managed for a senior comprehensive show her sophomore year, an adaptation of “Women Playing Hamlet.”“I only have experience acting in one comprehensive,” she said. “But, I like it more than the main stage shows because I like the student collaboration. These shows are low-pressure ways of getting into theatre. With stage managing, I learned a lot more because I was learning alongside the student in charge of her comp. I saw what she had to prepare and the work that really goes into these shows.” Those who are interested in theatre can also attend the American College Theatre Festival (ACTF), which is a regional event that allows students to attend workshops and see shows other schools have worked on during the year. Madison College in Wisconsin will host this year’s festival from Jan. 8-13, and Johnson said she will be preparing for the trip by finding lodging and making sure everyone can participate in the festival each day it runs. Johnson said students can attend regardless of whether or not they are theatre majors.“ACTF is a national theatre festival,” she said. “It helps theatre enthusiasts grow in their specific interests while introducing them to new people.” Both Strom and Johnson have been nominated for the Irene Ryan Acting Scholarship in past years. In order to qualify for this scholarship, students must attend ACTF and perform a two-minute scene and a one-minute monologue for a panel of judges. Strom said ACTF is a great opportunity to network and support other theatre students at nearby colleges. “The festival is a good experience and a great way to see what other schools are doing in their theatre programs,” she said.Johnson said students do not have to be theatre majors to appreciate theatre. Participating in theatre in college can help students “gain new skills and make new friendships,” she said. Watching live theatre can be an “exercise in empathy,” she added. “Theatre is about human stories,” Johnson said. “Watching live theatre is watching the stories of the struggles we all face.”
Osterholm MT. Author interviews with Michael Osterholm. May 3 and Aug 2, 2007 WHO. Global Advisory Committee on Vaccine Safety, 6-7 June 2006. Meeting report released Jun 14, 2006 [Full text] Schwartz SI. Atomic audit : the costs and consequences of U.S. nuclear weapons since 1940. Washington, DC: Brookings Institution Press, 1998 Fedson DS. Author interview with David Fedson. Jun 19, 2007 CDC. State-specific influenza vaccination coverage among adults aged >/= 18 years—United States, 2003-04 and 2005-06 influenza seasons. MMWR 2007 Sep 21;56(37):953-9 [Full text] HHS. HHS awards two contracts to expand domestic vaccine manufacturing capacity for a potential influenza pandemic. Jun 14, 2007 [Full text] Fauci AS. Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect Dis 2006 Nov 1;194(suppl 2):S73-6 [Full text] CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005 Jul 29;54(RR08):1-40 [Full text] Osterholm MT. Preparing for the next pandemic. Foreign Aff 2005 Jul/Aug;84(4) [Full text] Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 Feb 15;256(7):685-96 [Abstract] WHO. Projected supply of pandemic influenza vaccine sharply increases. Oct 23, 2007 [Press release] Keitel W. A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy adults. Presented at the Options for the Control of Influenza VI meeting, Toronto, Jun 2007 Lowen AC, Mubareka S, Tumpey TM, et al. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci 2006 June 27;103(26):9988-92 [Full text] Wood JM. International standards for H5N1 antibodies. Presented at the 3rd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, Geneva, Feb 15-16, 2007 [Full text] Stephenson I, Bugarini R, Nicholson KG, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005 Apr 15;191(8):1210-5 [Full text] Goodman J. How fast can a new vaccine for an emerging respiratory virus be developed and available for use? Presented at the International Conference on Emerging Infectious Diseases, Atlanta, GA, Mar 22, 2006 Leroux-Roels K, Borkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007 Aug 18;370(9587):580-9 [Abstract] Novartis. Novartis gains European approval for its innovative flu vaccine Optaflu. Jun 13, 2007, news release Poland GA. Vaccines against avian influenza—a race against time. (Editorial) N Engl J Med 2006 Mar 30;354(13):1411-3 [Full text] Stephenson I, Gust I, Pervikov Y, et al. Development of vaccines against influenza H5. Lancet Infect Dis 2006 Aug;6(8):458-60 Fedson DS, Dunnill P. New approaches to confronting an imminent influenza pandemic. (Commentary) Perm J 2007 Summer;11(3):63-9 [Full text] NIAID (National Institute of Allergy and Infectious Diseases). Report of the Blue Ribbon Panel on Influenza Research. Bethesda, Md., Sep 11-12, 2006. Posted Jun 2007 [Full text] Kreijtz JH, Bodewes R, van Amerongen G, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007 Jan 8;25(4):612-20 [Abstract] Protein Sciences Corp. Influenza vaccines under development. 2007 [Web page] BD. Author interview with George Goldman, Senior Director, Hypodermic Divison, BD Medical Surgical Systems. Jul 25, 2007 Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004 Oct 1;39(7):920-7 [Full text] GAO. Flu vaccine: steps are needed to better prepare for possible future shortages. Testimony by Janet Heinrich before US Senate Special Committee on Aging. GAO-01-786T. May 30, 2001 [Full text] FDA. Vaccines and Related Biological Products Advisory Committee meeting transcript. Feb 27, 2007 [Full text] Petrovsky N. New-age vaccine adjuvants: friend or foe? BioPharm Int Aug 2, 2007 WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO, 10 Sep 2007 Nicholson KG, Colegate AE, Podda A, et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001 Jun 16;357(9272):1937-43 [Abstract] Gosling FG. The Manhattan Project: making the atomic bomb. Oak Ridge, TN: US Department of Energy History Division, Jan 1999 Germann TC, Kadau K, Longini IR, et al. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci 2006 Apr 11;103(15):5935-40 [Abstract] Grady D. With few suppliers of flu shots, shortage was long in making. New York Times. Oct 17, 2004 [Full text] GSK (GlaxoSmithKline). Backgrounder: Egg-based vs. cell-based influenza vaccine production. 2005 GSK. GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development. Jan 17, 2007 [Press release] Smith GJD, Fan XH, Wang J, et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci 2006 Nov 7;103(45):16936-41 [Abstract] Working Group for Pandemic Influenza Preparedness. Letter to Congress. May 23, 2006 Heilman C. Author interviews with Carole Heilman. Sep 13 and Sep 24, 2007 Novartis. Novartis receives US government contract to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak. Jan 17, 2007, news release [Full text] Vajo Z, Kosa L, Visontay I, et al. Inactivated whole virus influenza A (H5N1) vaccine. (Letter) Emerg Infect Dis 2007 May;13(5) (published online Mar 29) [Full text] McKenna M. System for global pandemic vaccine development challenged. Minneapolis, MN: CIDRAP News, Feb 6, 2007 [Full text] IDSA (Infectious Diseases Society of America). Pandemic and seasonal influenza principles for US action. Released Jan 25, 2007 [Full text] ECDC (European Centre for Disease Prevention and Control). ‘Pre-pandemic’ vaccines might offer protection but uncertainties remain. Sep 20, 2007 [Press release] IOM. Vaccines for the 21st century. Released Mar 1999 [Full text] HHS (Department of Health and Human Services). HHS awards contracts totaling more than $1 billion to develop cell-based influenza vaccine. May 4, 2006 [Full text] IOM (Institute of Medicine). New vaccine development. 1985;1 The series: The pandemic vaccine puzzle FDA. Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. May 31, 2007 [Full text] GAO (Government Accountability Office, formerly General Accounting Office). Flu vaccine: recent supply shortages underscore ongoing challenges. Testimony by Janet Heinrich before House Subcommittee on Health, Subcommittee on Oversight and Investigations, and Committee on Energy and Commerce. GAO-05-177T. Nov 18, 2004 [Full text] McKenna M. Virus ownership claims could disrupt flu vaccine system. Minneapolis, MN: CIDRAP News. Jun 19, 2007 [Full text] Palkonyay L. Personal communication from Laszlo Palkonyay, MD, medical officer, WHO Initiative for Vaccine Research. Oct 25, 2007 Lin J, Zhang J, Dong X, et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006 Sep 16;368(9540):991-7 [Abstract] Lipatov AS, Webby RJ, Govorkova EA, et al. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005 Apr 15;191(8):1216-20 [Full text] Bosch Technologies. Author interview with Eric Isberg, Jack Lysfjord, and Tony Miller. Aug 3, 2007 CDC. Isolation of avian influenza A(H5N1) viruses from humans—Hong Kong. May-December 1997. MMWR 1997 Dec 19;46(50):1204-7 [Full text] Editor’s note: This is the bibliography to a seven-part series launched October 25, 2007, investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame. Treanor JJ, Schiff GM, Hayden FG, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007 Apr 11;297(14):1577-82 [Abstract] Trust for America’s Health/Infectious Diseases Society of America. Pandemic influenza: the state of the science. Oct 2006 [Full text] Monto A. Author interview with Arnold Monto. Aug 2, 2007 Trust for America’s Health. Flu spending update: pandemic planning and resource allocation. 2007 Luke CJ, Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006 Jan;12(1):66-72 [Full text] NIH (National Institutes of Health). Flu 2001-2008 estimated budget numbers spreadsheet, compiled for the author by NIH press office. 2007 Rosenwald MS. FluMist gets a needed boost: refrigerated version cleared. Washington Post. Jan 9, 2007 [Full Text] ECDC. Technical report: Expert advisory groups on human H5N1 vaccines: scientific questions. Aug 2007 [Full text] Govorkova EA, Webby RJ, Humberd J, et al. Immunization with reverse-genetics–produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006 Jul 15;194(2):159-67 [Full text] Thomas A, Guldager N, Hermansen K. Pandemic flu preparedness: a manufacturing perspective. BioPharm Int 2007 Aug (supp) (published online Aug 2) Goodman J. Considerations in the pre- and early pandemic use of influenza vaccine. Presented at FDA Center for Biologics Evaluation and Research Vaccines and Related Biological Products Advisory Committee Meeting, Gaithersburg, MD, Feb 27, 2007 Longini IM, Nizam A, Xu S, et al. Containing pandemic influenza at the source. Science 2005 Aug 12;309(5737):1083-7 [Abstract] Part 1: Flu research: a legacy of neglectPart 2: Vaccine production capacity falls far shortPart 3: H5N1 poses major immunologic challengesPart 4: The promise and problems of adjuvantsPart 5: What role for prepandemic vaccination?Part 6: Looking to novel vaccine technologiesPart 7: Time for a vaccine ‘Manhattan Project’?Bibliography [you are here] Ferguson NM, Cummings DA, Fraser C, et al. Strategies for mitigating an influenza pandemic. (Letter) Nature 2006 Jul 27;442(7101):448-52 [Abstract] WHO. Global pandemic influenza action plan to increase vaccine supply. Released Oct 23, 2006 [Full text] Sanofi Pasteur. Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility. Jul 20, 2007, news release [Full text] Hoffenbach A. Update of Sanofi Pasteur EU pandemic vaccine clinical development. Presented at the 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 14, 2007 [Full text] Santoli J. Influenza vaccine distribution data and use of data during the 2006-07 season. Presented at the National Influenza Vaccine Summit, Atlanta, Apr 2007 [Presentation] Stephenson I, Gust I, Kieny MP, et al. Development and evaluation of influenza pandemic vaccines. Lancet Infect Dis 2006 Feb;6(2):71-2 Riley S, Wu JT, Leung GM. Optimizing the dose of pre-pandemic influenza vaccines to reduce the infection attack rate. PLoS Med 2007 Jun;4(6):e218 [Full text] Strikas R. Pandemic influenza vaccine supply issues. Presented at the National Vaccine Advisory Committee Pandemic Influenza Working Group Meeting, Washington, DC, Apr 20, 2005 Kotalik J. Preparing for an influenza pandemic: ethical issues. Bioethics 2005 Aug;19(4):422-31 [Abstract] Fedson DS, Dunnill P. From scarcity to abundance: pandemic vaccines and other agents for “have not” countries. (Commentary) J Public Health Policy 2007;28(3):322-40 [Abstract] Acambis PLC. Acambis’ universal influenza vaccine enters phase 1 trial. Jul 17, 2007 Wood JM. Reference viruses for seasonal and pandemic influenza vaccine preparation. Influenza Other Respir Virus 2007 Jan;1(1):5-9 [Abstract] Bresson JL, Perrone C, Launay O, et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006 May 20;367(9523):1657-64 [Abstract] Treanor JJ (for Goji NA, Nolan C, Hill H, et al). Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. Presented at 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 15-16, 2007 [Full text] Wood JM. Author interview with John Wood. Jun 18, 2007 Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003 Jun 15;36(12):1552-61 [Full text] Working Group for Pandemic Influenza Preparedness. Letter to Congress. Nov 10, 2005 [Full text] Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007 April;7(4):267-78 [Abstract] OIE (World Organization for Animal Health). Update on avian influenza in animals (type h5), 15 Sep 2007 [Link updated regularly] Frist W. The Manhattan project for the 21st century. Presented at Nantucket Atheneum, Nantucket, MA, Aug 3, 2005 [Full text] GAO. Flu vaccine: supply problems heighten need to ensure access for high-risk people. Report to Congressional Requestors. GAO-01-624. May 15, 2001 [Full text] Treanor JJ, Schiff GM, Couch RB, et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006 May 1;193(9):1223-8 [Full text] Novartis. Flu Cell Culture Technology: The Next Frontier. 2006 Royal Society. Pandemic influenza: science to policy. Nov 2006 [Full text] Hehme N. GSK’s pandemic vaccine development: from 1st to to 2nd generation candidate vaccines. Presented at the 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Geneva, Feb 15-16, 2007 [Full text] FDA. Guidance for industry: Clinical data needed to support the licensure of seasonal inactivated influenza vaccines. May 31, 2007 [Full text] WHO. WHO consultation on priority public health interventions before and during an influenza pandemic. Apr 27, 2004 Treanor JJ, Campbell JD, Zangwill KM, et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006 Mar 30;354(13):1343-51 [Full text] Stephenson I, Nicholson KG, Wood JM, et al. Confronting the avian influenza threat: vaccine development for a potential pandemic. Lancet Infect Dis 2004 Aug;4(8):499-509 [Abstract] Schwartz B, Gellin B. Vaccination strategies for an influenza pandemic. (Commentary) J Infect Dis 2005 Apr 15;191(8):1207-9 [Full text] EMEA (European Medicines Agency). Guideline on adjuvants in vaccines for human use. Jan 20, 2005 [Full text] Fraser C. Influenza pandemic vaccines: spread them thin? PLoS Med 2007 Jun;4(6):e228 [Full text] Haaheim L. Vaccines for an influenza pandemic: scientific and political challenges. Influenza Other Respir Virus 2007;1(2):55-60 [Abstract] Lauerman J. Glaxo, Novartis, hurt by drug setbacks, may lose flu-shot race. Bloomberg News. Aug 23, 2007 [Full text] Working Group for Pandemic Influenza Preparedness. Letter to Congress. Jun 5, 2007 Poland GA. Author interview with Gregory Poland. Aug 1, 2007 Kresse H. Author interview with Hedwig Kresse. Aug 2, 2007 Zangwill K, Campbell J, Noah D, et al. Evaluation of a third dose of subvirion H5N1 influenza vaccine (rgA/Vietnam/1203/04 x PR8) in healthy adults. Presented at Options for the Control of Influenza VI, Toronto, Jun 17-23, 2007 Iomai. Iomai awarded government contract, totaling $128 million, to develop dose-sparing patch for use in an influenza pandemic. Jan 17, 2007 [Press release] Crosby AW. America’s forgotten pandemic: the influenza of 1918. Cambridge [England]; New York, Cambridge University Press, 1989
Topics : The app, which is not available in China, has sought to distance itself from its Chinese roots to appeal to a global audience and has emphasized its independence from China.Pompeo’s remarks also come amid increasing US-China tensions over the handling of the coronavirus outbreak, China’s actions in Hong Kong and a nearly two-year trade war.TikTok, a short-form video app owned by China-based ByteDance, was recently banned in India along with 58 other Chinese apps after a border clash between India and China.Reuters reported late on Monday that TikTok would exit the Hong Kong market within days, deciding to do so after China’s establishment of a sweeping new national security law for the semi-autonomous city. Secretary of State Mike Pompeo said late on Monday that the United States is “certainly looking at” banning Chinese social media apps, including TikTok.”I don’t want to get out in front of the President (Donald Trump), but it’s something we’re looking at,” Pompeo said in an interview with Fox News.US lawmakers have raised national security concerns over TikTok’s handling of user data, saying they were worried about Chinese laws requiring domestic companies “to support and cooperate with intelligence work controlled by the Chinese Communist Party.”
The four coalition partners making up the Netherlands’ new government have said they aim to conclude an accord for a new pensions contract early in 2018.Their governing agreement – presented yesterday – made clear that the cabinet would also provide clarity about how a transition from average to age-related “degressive” pensions accrual would take shape.The necessary legislation must be approved by parliament by 2020 before the implementation of the new arrangements can start.In the governing accord, the coalition partners – the liberals (VVD), the Christian democrats (CDA), liberal democrats (D66) and small religious-right party CU – said that they would increase the freedom of choice for pension fund participants by introducing the option of a lump sum at retirement. They also promised that the government would contribute to the transition costs – largely as a compensation for the affected participants – to degressive pensions accrual. Costs have been estimated at between €25bn and €100bn.The coalition agreement also indicated that the new cabinet, which is still to be constructed, would keep the principle of mandatory participation. This comes despite three of the coalition partners initially advocating freedom to pick a pensions provider.The four parties also said that they would facilitate the collective transition of existing pension claims into individual pension assets.The new pensions contract is most likely to comprise individual pensions accrual combined with a certain amount of collective risk sharing, and is to be added to the existing range of pension arrangements.Recently, the coalition partners said they wanted to enable the social partners of employers and workers – which have been discussing the issue in the Social and Economic Council (SER) for the past two years – to come up with their own proposals.Commenting on the government’s plans, the Netherlands’ Bureau for Economic Policy Analysis (CPB), said that abolishing average pensions accrual would be bad for purchasing power. It estimated that combined pension contributions would have to rise by €1bn.The coalition agreement also said that deploying pension assets to pay off a mortgage would not be possible for the time being. This option would be looked at after the reform of the pensions system has been completed, the parties said.The governing accord did not mention plans to further limit the tax-facilitated pensions accrual either. Currently, the annual tax-friendly accrual is 1.875% for a salary of up to €103,317.The agreement explicitly stated that the new government rejected additional European pension rules, emphasising that “the pensions system would remain a local competence”.The new coalition government must operate cautiously, as it has the smallest possible majority in parliament.As a consequence, three of the four political leaders won’t take up a ministerial post, but instead will stay on as chair of their respective parliamentary parties.The new cabinet will again be headed by VVD leader Mark Rutte, who has been prime minister for the past two Dutch parliaments.
While teams have played behind closed doors for the odd game, it is rather unusual for league matchups. read also:Eagles’ stars in Epl may undergo bi-weekly covid-19 test It is unclear how empty stadiums would impact the home advantage that teams usually enjoy in league fixtures. There is a league meeting on Friday to work on plans for a return to competitive action sometime in June. FacebookTwitterWhatsAppEmail分享 Promoted ContentTV Characters Who Hated Each Other But Later Became FriendsTop 10 Most Romantic Nations In The World5 Of The World’s Most Unique Theme ParksTop 8 Most Fun Sylvester Stallone MoviesCouples Who Celebrated Their Union In A Unique, Unforgettable Way7 Universities In The World Where Education Costs Too Much9 Facts You Should Know Before Getting A TattooTop 9 Scariest Haunted Castles In Europe5 Of The World’s Most Unique Theme ParksFantastic-Looking (and Probably Delicious) Bread ArtBest & Worst Celebrity Endorsed Games Ever Made10 Risky Jobs Some Women Do Premier League is making plans to stage friendly games so players can prepare before competitive action begins. It is not only going to help the players with their fitness, but these matches will be used as a trial of football without crowds. The Daily Mailreports that the league will be organising these friendlies at stadiums in accessible areas before the 19-20 season resumes. “You can do all the training in the world but it just doesn’t replicate the realism of a match,” one coach at a top-flight club told the source.Advertisement Loading…